When should iron sucrose (Venofer) be administered?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

When to Give Venofer (Iron Sucrose)

Venofer should be administered for iron deficiency anemia in chronic kidney disease patients, and as first-line therapy in inflammatory bowel disease patients with active disease, hemoglobin <10 g/dL, oral iron intolerance, or need for ESAs.

Primary Indications by Disease State

Chronic Kidney Disease (CKD)

Venofer is FDA-approved specifically for iron deficiency anemia in CKD patients 1. The KDIGO 2026 guidelines provide the most current framework 2:

Hemodialysis-dependent CKD (HDD-CKD):

  • Administer 100 mg IV per hemodialysis session (early in session, within first hour)
  • Total treatment course: 1000 mg
  • Dosing: Either undiluted over 2-5 minutes or diluted in 100 mL normal saline over ≥15 minutes 1

Non-dialysis dependent CKD (NDD-CKD):

  • 200 mg IV on 5 occasions over 14 days
  • Alternative: 500 mg infusions on Day 1 and Day 14 (diluted in 250 mL normal saline over 3.5-4 hours) 1

Peritoneal dialysis-dependent CKD (PDD-CKD):

  • Three divided doses over 28 days: 300 mg over 1.5 hours (Day 1), 300 mg over 1.5 hours (Day 15), 400 mg over 2.5 hours (Day 29) 1

Inflammatory Bowel Disease (IBD)

The 2015 ECCO guidelines establish clear first-line indications 3:

Mandatory IV iron situations:

  • Clinically active IBD
  • Previous oral iron intolerance
  • Hemoglobin <10 g/dL
  • Patients requiring erythropoiesis-stimulating agents

Dosing by hemoglobin and weight:

  • Hb 10-12 g/dL (women) or 10-13 g/dL (men): 1000 mg if <70 kg, 1500 mg if ≥70 kg
  • Hb 7-10 g/dL: 1500 mg if <70 kg, 2000 mg if ≥70 kg 3

Important caveat: While ferric carboxymaltose is preferred in IBD due to higher single-dose capacity (up to 1000 mg vs. 200 mg for iron sucrose), iron sucrose remains effective but requires multiple visits—typically 200-300 mg per treatment episode 3.

Other Validated Indications

Restless Legs Syndrome: The 2026 Mayo Clinic algorithm recommends IV iron when 4:

  • Serum ferritin 75-300 μg/L with TSAT <45%, OR
  • Serum ferritin <75 μg/L with TSAT <45% AND oral iron has failed/not tolerated/GI disease prevents absorption/severe RLS requiring rapid response

Pregnancy-related anemia:

  • Second and third trimester with Hb <9 g/dL
  • Optimal timing: <34 weeks gestation with ≥6 weeks latency before delivery
  • Doses ≥800 mg show superior outcomes (Hb increase 2.6-3.1 g/dL) 5
  • Standard regimen: Three 200 mg doses on consecutive days 6, 7

Heart Failure with reduced ejection fraction:

  • LVEF ≤40% with iron deficiency (ferritin <100 ng/mL OR ferritin 100-299 ng/mL with TSAT <20%)
  • Improves quality of life and corrects iron stores 8

When NOT to Use Venofer

Absolute contraindications:

  • Known hypersensitivity to iron sucrose 1
  • TSAT >45% (risk of hepatic iron overload) 4

Relative contraindications/cautions:

  • Active systemic infection (temporarily suspend) 2
  • Transferrin saturation >50% and ferritin >800 μg/L in IBD patients 3

Dosing Limitations Specific to Iron Sucrose

Unlike newer formulations, iron sucrose has strict maximum single-dose limits 2, 9:

  • Maximum single dose: 200 mg (CKD patients)
  • Maximum single dose: 400 mg (PD patients only)
  • Minimum infusion time: 15 minutes for maximum dose 2

This limitation means iron sucrose requires multiple patient visits to deliver total iron repletion doses of 1000+ mg, making it less convenient than ferric carboxymaltose (1000 mg single dose) or ferric derisomaltose (up to 20 mg/kg single dose) 2, 9.

Monitoring and Retreatment

Timing of laboratory assessment:

  • Do NOT check iron parameters within 4 weeks of last infusion (circulating iron interferes with assays) 10
  • Check CBC and iron parameters 4-8 weeks post-treatment 10
  • CKD patients: Every 1-3 months for dialysis patients, every 3 months for non-dialysis 2

Expected response:

  • Hemoglobin should increase 1-2 g/dL within 4-8 weeks 10
  • IBD patients: ≥2 g/dL increase within 4 weeks is acceptable 3

Retreatment criteria:

  • When iron deficiency recurs (document with ferritin and TSAT) 1
  • Maintenance dosing in hemodialysis: 0.5 mg/kg every 2 weeks for pediatrics 1

Safety Considerations

Hypersensitivity risk:

  • Serious reactions including anaphylaxis can occur but are rare (<0.1%) 11
  • Monitor patients for ≥30 minutes after infusion 1
  • Resuscitation facilities must be available 12
  • No test dose required for iron sucrose (unlike iron dextran) 3, 2

Hypophosphatemia: Iron sucrose has significantly lower risk of hypophosphatemia compared to ferric carboxymaltose (2.3% vs. 47%) 11. This makes iron sucrose preferable for patients requiring repeated infusions.

Infusion reactions: Most adverse events are minor (nausea, injection site pain, mild hypotension) and occur in <13% of patients 13, 6. Serious adverse events are extremely rare with proper administration 13.

Practical Algorithm

  1. Confirm iron deficiency anemia (low Hb + low ferritin or TSAT <20%)
  2. Identify indication: CKD, active IBD, pregnancy, heart failure, or RLS
  3. Check contraindications: Known allergy, TSAT >45%, active infection
  4. Choose iron sucrose when:
    • Patient has CKD (FDA-approved indication)
    • Ferric carboxymaltose unavailable or contraindicated (need to avoid hypophosphatemia)
    • Cost considerations favor iron sucrose
  5. Dose according to indication (see specific regimens above)
  6. Monitor during infusion for 30+ minutes
  7. Reassess 4-8 weeks post-treatment with CBC and iron studies
  8. Retreat if iron deficiency recurs

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.